Mr. Market unimpressed by this, nevertheless, we can mark our calendars:
>>BRISBANE, Calif., April 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - News) announced today that results of a randomized, double-blind, placebo-controlled Phase II clinical trial evaluating Actimmune's® (interferon gamma-1b) influence on several underlying mechanisms of action in idiopathic pulmonary fibrosis (IPF) will be presented at the 99th Annual Conference of the American Thoracic Society (ATS) next month in Seattle. The molecular measures associated with IPF, a debilitating and fatal lung disease, include measures of fibrosis, antimicrobial activity, growth factors and inhibitors of angiogenesis.
Full results of this trial, which involved 32 patients, will be presented on Sunday, May 18, at ATS in Seattle by Robert M. Strieter, M.D., Professor of Medicine and Pathology and Chief, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA in Los Angeles.
"The purpose of this trial was to understand the biological basis for interferon gamma-1b treatment in IPF and extend our knowledge of its effects in IPF at the molecular level," said Dr. Strieter. "These results help provide a plausible hypothesis for the mechanism of action of interferon gamma-1b in IPF. We are excited by these results and look forward to sharing them in more detail at the ATS meeting in May."<<
snip
Cheers, Tuck |
